---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-125350"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T08:42:49.331448+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics CEO Russell Trenary resigns effective Dec 3; CFO Kenyon named interim CEO

## Summary
- C. Russell Trenary III stepped down as President, CEO and Board member on Dec 3, 2024, effective immediately.
- Departure is a termination without cause; Trenary will receive severance benefits per his employment agreement.
- Board reduced from ten to nine directors upon Trenary's resignation.
- CFO Lawrence A. Kenyon, 59, appointed Interim CEO effective Dec 3 while Board searches for permanent CEO.
- Kenyon continues as CFO during the interim period; no material arrangements or family relationships disclosed.

## SEC filing metadata
- accession: 0001104659-24-125350
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465924125350/0001104659-24-125350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465924125350/tm2430072d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-125350
- JSON: https://secwatch.observer/filing/0001104659-24-125350.json
- Plain text: https://secwatch.observer/filing/0001104659-24-125350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.